Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.4K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.4K
Bone Formation by Endochondral Ossification01:24

Bone Formation by Endochondral Ossification

8.0K
Bone formation, or ossification, begins around the sixth to seventh week of embryonic development. Most bones develop from a cartilaginous template through the process of endochondral ossification. Cartilage formation begins when clusters of mesenchymal cells differentiate into chondrocytes. These chondrocytes proliferate rapidly and secrete an extracellular matrix that becomes encased in a membrane called the perichondrium. The resulting cartilage model provides a template that resembles the...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perineurioma-like EMA-positive calvarial neoplasms: clinicopathological study of eight cases.

Histopathology·2026
Same author

Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Robust Four-Field and Arc LET-Optimized Proton Prostate Cancer Treatment Plans With Urethral Sparing.

International journal of particle therapy·2026
Same author

Particle Therapy Co-Operative Group Consensus Statement on Reirradiation With Proton Therapy for Prostate Cancer.

International journal of particle therapy·2026
Same author

Ten-year outcomes for image-guided moderately hypofractionated proton therapy for prostate cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Does This Imaging Make Me Look NFATC2 ? The Value of Radiologic-pathologic Correlation in NFATC2 -rearranged Sarcomas of Bone.

The American journal of surgical pathology·2026
Same journal

Validation of the Effectiveness of Visual Feedback Systems in Respiratory Gating Carbon Ion Radiation Therapy.

International journal of particle therapy·2026
Same journal

Emerging Outcome Trends From Proton Therapy for Pediatric CNS Tumors: A Systematic Review.

International journal of particle therapy·2026
Same journal

Biologically Effective Dose-Optimized Multi-Intensity-Modulated Proton Therapy: A Biologically Comparable Alternative to Proton Arc Therapy.

International journal of particle therapy·2026
Same journal

Proton Therapy for Head and Neck Adenoid Cystic Carcinoma: A Multi-institutional Review.

International journal of particle therapy·2026
Same journal

Characterization of a Low-Energy Cyclotron-Based Proton Beam for Preclinical Radiobiological Studies.

International journal of particle therapy·2026
Same journal

Phenomenological Study of Intra-Spill Break Spots in Dose-Driven Continuous Scanning Proton Therapy.

International journal of particle therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K

Mesenchymal Chondrosarcoma.

William M Mendenhall1,2, John D Reith3, Mark T Scarborough4

  • 1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA.

International Journal of Particle Therapy
|November 28, 2019
PubMed
Summary
This summary is machine-generated.

Mesenchymal chondrosarcoma (MC) treatment focuses on surgery, with adjuvant therapies considered for high-risk cases. Outcomes show moderate survival rates, emphasizing the need for careful management of this rare bone and soft tissue cancer.

Keywords:
mesenchymal chondrosarcomasoft tissue sarcoma

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.2K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Related Experiment Videos

Last Updated: Jan 3, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.6K
The In ovo CAM-assay as a Xenograft Model for Sarcoma
12:44

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

26.2K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.8K

Area of Science:

  • Oncology
  • Surgical Pathology
  • Cancer Therapeutics

Background:

  • Mesenchymal chondrosarcoma (MC) is a rare, aggressive small round blue cell malignancy.
  • It can arise in bone or soft tissue, typically affecting individuals in their second or third decade.
  • Patients often present with pain and swelling, and 15% have distant metastases at diagnosis.

Purpose of the Study:

  • To review the treatment strategies and patient outcomes for mesenchymal chondrosarcomas (MC).

Main Methods:

  • A comprehensive review of the existing medical literature on mesenchymal chondrosarcoma.

Main Results:

  • Optimal treatment involves surgery; adjuvant chemotherapy (e.g., anthracycline-based regimens) and radiation therapy are considered for specific cases with positive margins or incomplete resection.
  • Recurrence, often via hematogenous spread, can occur late, with salvage rates being modest.
  • Overall 5-year survival is approximately 50%, improving to 70-80% for localized disease treated with resection.

Conclusions:

  • Surgery is the primary treatment for mesenchymal chondrosarcoma.
  • Adjuvant chemotherapy should be considered for medically fit patients due to the high recurrence risk.
  • Radiation therapy is recommended for tumors with inadequate margins or incomplete resection.